Onkologie up2date, Table of Contents Onkologie up2date 2020; 2(02): 123-136DOI: 10.1055/a-1124-9335 Tumoren der endokrinen Organe Georg Thieme Verlag KG Stuttgart · New YorkNeuroendokrine Tumoren im Gastrointestinaltrakt Authors Lutz Philipp Breitling Anja Rinke Thomas Mathias Gress Recommend Article Abstract Buy Article(opens in new window) All articles of this category(opens in new window) Neuroendokrine Neoplasien sind eine heterogene Gruppe von Tumoren, deren Diagnosehäufigkeit seit Jahrzehnten stark zunimmt. Damit steigt bei oft gutem Langzeitüberleben die Wahrscheinlichkeit, in der Praxis auf NEN-Patienten zu treffen. Dieser Beitrag gibt einen praxisnahen Überblick über klinische, diagnostische und therapeutische Besonderheiten. Ausführlichere Beschreibungen bietet die aktuelle deutsche S2k-Leitlinie Neuroendokrine Tumoren [1]. Full Text References Literatur 1 Rinke A, Wiedenmann B, Auernhammer C. et al. S2k-Leitlinie Neuroendokrine Tumore. Z Gastroenterol 2018; 56: 583-681 2 Dasari A, Shen C, Halperin D. et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017; 3: 1335-1342 doi:10.1001/jamaoncol.2017.0589 3 Lloyd RV, Osamura RY, Klöppel G. et al. WHO Classification of endocrine Organs. 4th ed. Geneva: WHO Press; 2017 4 Halperin DM, Shen C, Dasari A. et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a populationbased study. Lancet Oncol 2017; 18: 525-534 doi:10.1016/S1470-2045(17)30110-9 5 Sundin A, Arnold R, Baudin E. et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging. Neuroendocrinology 2017; 105: 212-244 doi:10.1159/000471879 6 Kulke MH, Hörsch D, Caplin ME. et al. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. J Clin Oncol 2017; 35: 14-23 doi:10.1200/JCO.2016.69.2780 7 Rinke A, Müller HH, Schade-Brittinger C. et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656-4663 doi:10.1200/JCO.2009.22.8510 8 Caplin ME, Pavel M, Ruszniewski P. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014; 371: 1556-1557 doi:10.1056/NEJMc1409757 9 Krug S, Boch M, Daniel H. et al. Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms – Predictive and Prognostic Markers for Treatment Stratification. PLoS One 2015; 10: e0143822..pone.0143822 doi:10.1371/journal 10 Dilz LM, Denecke T, Steffen IG. et al. Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours. Eur J Cancer 2015; 51: 1253-1262 doi:10.1016/j.ejca.2015.04.005 11 Cives M, Ghayouri M, Morse B. et al. Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. Endocr Relat Cancer 2016; 23: 759-767 doi:10.1530/ERC-16-0147 12 Mueller D, Krug S, Majumder M. et al. Low dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumors. BMC Cancer 2016; 16: 645 doi:10.1186/s12885-016-2642-1 13 Yao JC, Shah MH, Ito T. et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523 doi:10.1056/NEJMoa1009290 14 Yao JC, Fazio N, Singh S. et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 2016; 387: 968-977 doi:10.1016/S0140-6736(15)00817-X 15 Raymond E, Dahan L, Raoul JL. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-513 doi:10.1056/NEJMoa1003825 16 Strosberg J, El-Haddad G, Wolin E. et al. Phase 3 Trial of (177) Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 2017; 376: 125-135 doi:10.1056/NEJMoa1607427 17 Strosberg JR, Weber JM, Feldman M. et al. Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors. J Clin Oncol 2013; 31: 420-425 doi:10.1200/JCO.2012.44.5924 18 Pape UF, Berndt U, Müller-Nordhorn J. et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2008; 15: 1083-1097 doi:10.1677/ERC-08-0017 19 Sorbye H, Strosberg J, Baudin E. et al. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer 2014; 120: 2814-2823 doi:10.1002/cncr.28721
